News & Updates
Filter by Specialty:
KangDuo Surgical Robot-01 system feasible for robot-assisted radical prostatectomy
Use of the KangDuo Surgical Robot-01 (KD-SR-01) system for the management of localized prostate cancer is safe and effective, according to the initial results of a prospective, single-centre study.
KangDuo Surgical Robot-01 system feasible for robot-assisted radical prostatectomy
24 Jun 2022
Colorectal cancer alters gut microbiome
Patients with colorectal cancer (CRC) have a substantially altered gut microbiome, characterized by changes in bacterial composition, according to a recent Singapore study. Of note, these alterations persist even after surgery.
Colorectal cancer alters gut microbiome
24 Jun 2022
Negative transrectal ultrasound biopsy tied to low prostate cancer death
Prostate cancer-specific mortality is very low among men with negative transrectal ultrasound (TRUS) biopsies, particularly those with prostate-specific antigen (PSA) <10 ng/ml, reports a study.
Negative transrectal ultrasound biopsy tied to low prostate cancer death
23 Jun 2022
Rare gene mutations predict prostate cancer relapse
Rare and deleterious germline mutations affecting inflammatory response and cellular signaling pathways associate strongly with the time to biochemical recurrence (BCR) after radical treatment in patients with prostate cancer (PrCa), according to a recent study.
Rare gene mutations predict prostate cancer relapse
23 Jun 2022
What causes death in bladder cancer patients?
Heart diseases, chronic obstructive pulmonary disease (COPD), concomitant cancers, and other co-occurring diseases elevate the risk of death in patients with nonmuscular invasive bladder cancer (NMIBC), nonmetastatic muscle invasive bladder cancer (non-MMIBC), and metastatic bladder cancer (MBC), according to a recent study.
What causes death in bladder cancer patients?
22 Jun 2022
Nintedanib falls short in bladder cancer trial
In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).